Takeda San Diego, Inc.

Takeda Pharmaceutical Company Limited

Takeda California, Inc.

Mingnam Tang

Zacharia S Cheruvallath

Stephen L Gwaltney

Jun Feng

Mark Sabat

Joanne Miura

Jeffrey Alan Stafford

Prasuna Guntupalli

Huikai Sun

Kristin Schleicher

Jason Green

Haxia Wang

Christopher McBride

John David Lawson

Sheldon Cao

Andrew John Jennings

Robert J Skene

Mallareddy Komandla

Ben Johnson

Stephen W Kaldor

Beverly Lynn Wolgast

Haixia Wang

Sean Timothy Murphy

David J Hosfield

Philip Erickson

Huong-Thu Ton-Nu

David J Hossfield

Christopher Mcbride

Sheldon X Cao

Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein n, R, R, R, R, R, R, R, R, R, R, X, Xand Xare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

Disclosed are compounds of Formula 1, stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R, R, R, R, R, R, R, X, X, X, X, X, and Xare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

Piperidinyl-3-(aryloxy)propanamides and propanoates

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, R, R, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Substituted-1,4-dihydropyrazolo[4,3-b]indoles

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, and Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

Indazole derivatives

Compounds are provided for use with glucokinase that comprise the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Glucokinase activators

Pyrazole and fused pyrazole glucokinase activators

Compounds of the following formula are provided for use with glucokinase: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Compounds are provided which have the formula: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture which contain such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to activate glucokinase.

Substituted isoindoles as glucokinase activators

Compounds are provided for use with hexokinases that comprise: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Substituted indazoles as glucokinase activators

Growing community of inventors

San Diego, CA, United States of America

Mingnam Tang